Comparison · NCT00422084-sae
PA Group vs AL Group: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. PA Group vs AL Group: serious adverse events. Trial comparisons, record NCT00422084-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00422084-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.00353 | 0.0012 | 0.0103 | wilson | |
| Risk in group 2 | 0.00473 | 0.0013 | 0.0171 | wilson | |
| Risk difference, group 1 minus group 2 | -0.00119 | -0.0138 | 0.00642 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.747 | 0.125 | 4.46 | log | |
| Odds ratio, group 1 over group 2 | 0.746 | 0.124 | 4.48 | log | |
| Number needed to treat, for one fewer participant with a serious adverse event on PA Group than on AL Group | 837 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | PA Group | Pyronaridine artesunate (PA)~Pyronaridine artesunate: Oral PA (180:60mg tablets) once a day plus AL-placebo (twice a day) for 3 consecutive days (Day 0, 1, and 2) | 3 | 849 | EG000 |
| Group 2 | AL Group | Arthemether lumefantrine (AL)~Coartem® (artemether lumefantrine): AL twice a day plus PA-placebo (once a day) for 3 consecutive days (Day 0, 1, and 2) | 2 | 423 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- Day 0 to 42. Subjects experiencing AEs at Day 42 were followed for up to 30 days after the end of study or resolution of the event, whichever was earlier
Source ClinicalTrials.gov
Trial
- Title
- Pyronaridine Artesunate (3:1) Versus Coartem® in P Falciparum Malaria Patients
- NCT number
- NCT00422084
- Phases
- PHASE3
- Conditions
- Malaria
- Interventions
- Pyronaridine artesunate, Coartem® (artemether lumefantrine)
- Lead sponsor
- Medicines for Malaria Venture
- Results first posted
- 2021-09-20
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00422084?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00422084-sae